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Introduction
Cerebral palsy (CP) describes a spectrum of 
movement disorders caused by a lesion of the 
developing brain.1,2 The upper motor neuron 
lesion impairs neuromotor development2 and 
results in a cascade of secondary musculoskeletal 
changes including muscle contractures.1 
Contracture development in individuals with CP 
is progressive and leads to a step-wise reduction 
in musculoskeletal development, muscle fatiga-
bility, and reduced physical activity.2 As a conse-
quence of poor muscle health and a sedentary 
lifestyle, the prevalence of chronic conditions 
such as diabetes, hypertension, and arthritis is 
greater in individuals with CP as compared to 
typically developed (TD) peers.3 In typically 
developing individuals, all of these impairments 
and conditions have been associated with 
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Abstract
Individuals with cerebral palsy (CP) develop skeletal muscle contractures that impair muscle function. In turn, contractures 
affect the ability to ambulate and often promote a sedentary lifestyle. The aim of the present study was to investigate the 
systemic inflammatory markers transforming growth factor beta-1 (TGFβ1), C-reactive protein (CRP), and interleukin-6 
(IL-6) in children and adults with CP. Blood samples of n = 34 participants (24 individuals with CP (n = 14 children with 
CP age 10.36 ± 1.1 and n = 10 adults with CP age 38.80 ± 3.6) and 10 healthy adults age 36.63 ± 3.8) were analyzed 
for circulating levels of TGFβ1, CRP, and IL-6 using Sandwich Enzyme linked immunosorbent assay (ELISA) analyses 
(R&D systems). TGFβ1 and CRP levels were significantly higher in children with CP compared to both adults with CP 
(TGFβ1: P < 0.0005 and P < 0.0002, respectively) and healthy adults (CRP: P < 0.0001 and P < 0.0001, respectively), 
while no differences were observed between the adults with CP and healthy adults in TGFβ1 (P = 0.29) and CRP 
(P = 0.59), respectively. Furthermore, IL-6 levels showed no significant differences between the groups. The present 
findings indicate that the level of systemic inflammation is increased in children with CP. We speculate that persisting 
inflammation in children with CP might influence the development of muscle contractures, resulting in reduced muscle 
mass and marked muscle weakness in adults with CP.
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elevated circulating systemic inflammatory 
markers, which can contribute to the develop-
ment or progression of certain conditions.4
Transforming growth factor beta-1 (TGFβ1) is 
one systemic pro-inflammatory cytokine that has 
been shown to influence muscle development and 
elevated mRNA levels of TGFβ1 and TGFβR2 
have been observed in muscle tissue of children 
with CP with fixed contractures.5 In addition, 
C-reactive protein (CRP) is another important sys-
temic inflammatory marker and indicator of mus-
cle tissue catabolism and previous findings have 
shown that CRP might have a direct negative influ-
ence on skeletal muscle cells and underlies the 
connection between poor muscle function and sys-
temic inflammation.6 Another pro-inflammatory 
cytokine that has received considerable attention in 
connection to exercise and muscle growth is inter-
leukin 6 (IL-6), as chronically elevated levels pro-
mote skeletal muscle wasting.7 Early and 
accelerated loss of strength and functional capa-
bilities occur in individuals with CP relative to 
healthy individuals.8 Little is known about what 
factors contribute to the decline. Systemic inflam-
matory cytokines and acute phase proteins may 
also affect muscle growth and quality and thus 
musculoskeletal development. Therefore, the aim 
of this study was to investigate the circulating lev-
els of TGFβ1, CRP, and IL-6 in children and adults 
with CP compared to typically developing healthy 
individuals.
Methods
Design
Thirty-four participants (24 individuals with CP 
and 10 healthy adult participants) were recruited to 
the study. Anthropometric data are presented in 
Table 1. Inclusion criteria of the individuals with 
CP: (1) clinical diagnosis of CP (brain lesion diag-
nosed within the first 2 years of life); (2) the clini-
cal history of each participant with CP and gross 
motor function classification system (GMFCS) 
scores are shown in Table 2. Exclusion criteria: 
Other brain lesion(s) that have been diagnosed 
after the first 2 years of life. The healthy partici-
pants were included in the study if they had no his-
tory of previous musculoskeletal disorders. The 
research protocol was approved by the Regional 
Ethics Committee for Copenhagen (H-4-2014-
047), in compliance with the Helsinki Declaration. 
Participants were recruited via the Orthopedic 
Department, University Hospital, Hvidovre, 
Denmark, or from the University of Copenhagen. 
All adult participants, and parent/guardian of child 
participants, gave informed consent to be involved 
in the study.
Blood samples were taken from n = 14 children 
with CP (CP_C), n = 10 adults with CP (CP_A), 
and n = 10 healthy adults (Con_A). All blood sam-
ples were taken in the morning while the partici-
pant rested in a quiet laboratory room. The blood 
samples of children were taken the day before a 
planned orthopedic surgery. All children were 
examined prior to surgery by the treating surgeon 
and considered medically healthy (without any 
present cold or flu infections) and able to proceed 
to surgery. Blood samples were taken from all 
adults with CP were also taken in a non-stressful 
environment 1–4 days before a planned orthopedic 
surgery, and from all healthy adults after inclusion 
in the study. Blood samples were collected using a 
butterfly needle (Terumo; cannula 0.8 × 19 mm, 
18 cm) from the antecubital vein in one arm and 
left on slush ice for 15 min before they were spun 
and plasma was removed. The plasma was stored 
at −80°C for subsequent Enzyme linked immuno-
sorbent assay (ELISA) analysis.
ELISA analysis
Samples were analyzed for TGFβ1, CRP, and IL-6 
using a quantitative sandwich enzyme immunoas-
say (all from R&D Systems, Minneapolis, MN, 
USA) in accordance with the manufacturer’s recom-
mendations. TGFβ1 ELISA: plasma samples were 
first activated and then neutralized according to the 
manufacturer’s instructions. Samples from all par-
ticipants were analyzed in the same assay. The mini-
mum detectable dose (MDD) ranged from 
1.7–15.4 pg/mL, and the intra-assay variation (coef-
ficient of variation) was 2.7%. Human CRP ELISA: 
plasma samples were diluted 100-fold according to 
Table 1. Subject characteristics.
Age (year) Height (m) Weight (kg) BMI (kg/m2)
CP children 10.36 ± 1.1 1.4 ± 0.1 34.8 ± 2.9 17.7 ± 0.7
CP adults 38.80 ± 3.6 1.7 ± 0.1 72.5 ± 3.4 26.4 ± 1.6
Con adults 36.63 ± 3.8 1.8 ± 0.1 77.0 ± 3.1 24.5 ± 0.6
BMI: body mass index; CP: cerebral palsy.
All data shown in mean ± SEM.
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Table 2. Clinical history of all patients.
Subject GMFCS Gender Classification Operation Previous Btx 
treatment
Oral antispastic 
treatment
Ambulation
CP child 1 1 F Hemiplegic Bilateral calf muscle 
elongation
Once 2 years before 
the study without 
effect
Baclofen yes with 
orthosis
CP child 2 1 M Diplegic Bilateral calf muscle 
elongation (twice)
No No yes
CP child 3 1 F Diplegic Bilateral calf muscle 
elongation
No No yes
CP child 4 1 F Hemiplegic Unilateral calf muscle 
elongation
No No yes
CP child 5 1 M Hemiplegic Unilateral calf muscle 
elongation
Regulary calf and hand 
treatments
No yes with 
orthosis
CP child 6 4 M Diplegic Bilateral calf muscle 
elongation
Regulary calf, 
hamstring, and hand 
treatments
Baclofen yes with 
orthosis and 
walker
CP child 7 4 M Diplegic Bilateral calf muscle 
elongation
Regulary calf and hand 
treatments
Baclofen yes with 
orthosis and 
walker
CP child 8 3 M Diplegic Bilateral calf muscle 
elongation
Once several years 
before the study 
without effect
No yes with 
orthosis and 
walker
CP child 9 2 F Diplegic Bilateral calf muscle 
elongation (twice)
Once several years 
before the study 
without effect
No yes with 
orthosis
CP child 
10
1 F Hemiplegic Unilateral calf muscle 
elongation (twice)
A few times several 
years before the study 
without effect
No yes with 
orthosis
CP child 
11
5 F Diplegic Bilateral calf muscle 
elongation and hip 
surgery
Regulary calf and hand 
treatments
Baclofen No but 
stands with 
walker
CP child 
12
4 M Tetraplegic Bilateral calf muscle 
elongation and hip 
surgery
Regulary treatments 
at several sites in both 
upper and lower limbs
Baclofen pump yes but only 
little with 
orthosis and 
walker
CP child 
13
3 M Diplegic Bilateral calf muscle 
elongation (several times)
No No yes with 
orthosis
CP child 
14
4 F Diplegic Bilateral calf muscle 
elongation (twice) and 
hamstring surgery
Regulary calf and 
hamstring treatments
Baclofen yes with 
orthosis and 
walker
CP adult 1 4 F Diplegic Bilateral calf muscle 
elongation (twice) and 
hamstring surgery
No Baclofen yes but only 
little with 
orthosis and 
walker
CP adult 2 2 M Hemiplegic – No No yes
CP adult 3 1 F Hemiplegic Unilateral calf muscle 
elongation
Yes regulary 
treatments
No yes
CP adult 4 1 M Diplegic Bilateral calf muscle 
elongation
No No yes
CP adult 5 1 M Hemiplegic Bilateral calf muscle 
elongation and hamstring 
surgery
No No yes
CP adult 6 1 F Diplegic Bilateral calf muscle 
elongation and hip 
surgery
No Baclofen yes
CP adult 7 1 M Hemiplegic Bilateral calf muscle 
elongation and hamstring 
surgery
No Aprofopam yes
(Continued)
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the protocol. Samples from all participants were 
analyzed in the same assay. The MDD ranged from 
0.005–0.022 ng/mL, and the intra-assay variation 
(coefficient of variation) was 5.5%. One CP-C sam-
ple was under the detectable range and the data were 
not included in the statistical analysis. IL-6 ELISA: 
MDD was less than 0.70 pg/mL, and the intra-assay 
variation (coefficient of variation) was 2.6%. In 
total, six samples were under the detectable range 
and not included in the statistical analysis. Final par-
ticipant data included in analysis were CP_C, n = 11 
(three missing samples); CP_A, n = 8 (two missing 
samples); and Con_A, n = 9 (one missing sample).
Statistics
All data are presented as mean ± SEM. Non-
parametric unpaired t-tests were used to analyze 
differences between the CRP, TGFβ1, and IL-6 
levels of the three groups. The level of significance 
was P < 0.05. All statistical analyses and Figure 1 
were generated in GraphPad Prism 6.04 (GraphPad 
Software, Inc., San Diego, CA, USA).
Results
TGFβ1 levels were significantly higher in children 
with CP (13.21 ± 2.31 pg/mL) compared to both 
adults with CP (1.97 ± 0.70 pg/mL; P < 0.0005) 
and healthy adults (1.19 ± 0.16 pg/mL; P < 0.0002) 
(Figure 1(a)). No differences were observed 
between adults with CP and healthy adults 
(P = 0.289). In the assay description from R&D 
systems, the normal level of TGFβ1 is stated to be 
lower than detection limit mean of 1165 pg/mL 
(measured in n = 23 healthy individuals).
The CRP levels of the children with CP 
(57.22 ± 17.98 ng/mL) were significantly higher 
when compared to both adults with CP 
(7.91 ± 2.21 ng/mL; P < 0.0001) and healthy 
adults (6.89 ± 2.66 ng/mL; P < 0.0001) (Figure 
1(b)). No differences were observed between 
adults with CP and healthy adults (P = 0.588). In 
the assay description from R&D systems, the nor-
mal level of CRP is stated to be lower than detec-
tion limit mean of 1547 ng/mL (measured in n = 35 
healthy individuals).
The IL-6 levels were also higher but not signifi-
cant in children with CP (2.61 ± 1.06 pg/mL) com-
pared to both adult groups (adults with CP: 
1.44 ± 0.49 pg/mL (P < 0.5916); healthy control 
adults: 1.25 ± 0.77 pg/mL (P < 0.51) (Figure 1(c))). 
In the assay description from R&D systems, it is 
stated the normal level of IL-6 in n = 33 healthy indi-
viduals was measured to be lower than detection 
limit (3.13 pg/mL), while n = 7 further individuals 
had IL-6 levels that ranged from 3.13 to 12.5 pg/mL.
Discussion
The present study shows that children with CP have 
significantly higher systemic levels of TGFβ1 and 
CRP, when compared to adults with CP and healthy 
adults and also when compared to TD child norma-
tive values.9 Persistent or recurrent elevated blood 
concentrations of inflammation-related proteins 
during the first two postnatal weeks in preterm 
infants are associated with CP10; however, little is 
known about elevated systemic inflammation and 
the effects thereof on neurological and/or musculo-
skeletal development of school-age children with 
CP. All children that were included in the present 
Subject GMFCS Gender Classification Operation Previous Btx 
treatment
Oral antispastic 
treatment
Ambulation
CP adult 8 4 F Diplegic Bilateral calf muscle 
elongation and hip 
surgery
No No yes but only 
little with 
orthosis and 
walker
CP adult 9 3 M Diplegic Bilateral calf muscle 
elongation
No No yes with 
orthosis
CP adult 
10
3 M Diplegic Bilateral calf muscle 
elongation (twice) and 
hamstring surgery
Regulary calf, 
hamstring, and hand 
treatments
No yes with 
orthosis
GMFCS: gross motor function classification system; CP: cerebral palsy.
Table 2. (Continued)
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study had muscle contractures and needed surgical 
corrections. It may be speculated that elevated lev-
els of multiple systemic inflammatory markers in 
this group of children were related to skeletal mus-
cle contractures. Systemic inflammation may be the 
consequence of the muscle tissue attempting to 
repair muscle damage following chronic overload.11 
In the growing muscle tissue of children with CP, 
systemic inflammation may also contribute to the 
failure of normal hypertrophic growth and tissue 
remodeling through a reduction of protein synthesis 
rate as previously observed in muscular dystro-
phies.12 Elevated levels of TGFβ1, CRP, and IL-6 
have been accompanied by reduced muscle mass,7 
indicating a catabolic effect of inflammation on 
muscle tissue. However, the present study can unfor-
tunately not conclude any cause and effect relation-
ship between systemic inflammation and severity of 
muscle contractures. The relationship between the 
severity of the brain lesion causing CP (as indicated 
by brain magnetic resonance imaging (MRI)) and 
levels of systemic inflammation may offer promis-
ing opportunities for future studies. One major 
drawback of the current study is the lack of blood 
samples from TD children. Therefore, the results 
from the present study cannot rule out that a general 
difference exists in inflammatory levels between 
children and adults, or individuals with differing 
levels of activity. However, all of our participants 
were considered medically healthy (no current 
infections/medical disorders); therefore, any sys-
temic inflammation was expected to be very low. 
Furthermore, in order to limit stress prior to surgery 
as a confounding factor, the blood samples have 
been taken at least 1 day before the surgical inter-
vention. The present study shows that systemic lev-
els of TGFβ1 and CRP are significantly increased in 
children with CP when compared to healthy adults 
and adults with CP. An inclusion of blood samples 
from TD children and CP children without muscle 
contractures and children who have different neuro-
muscular disorders might offer interesting and 
important extensions of this study.
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Figure 1. (a) Plasma TGFβ1 levels shown in picograms per 
milliliter (pg/mL), (b) plasma CRP levels shown in nanograms 
per milliliter (ng/mL), and (c) plasma IL-6 levels shown in 
picograms per milliliter (pg/mL). No significant differences 
in IL-6 levels were observed between the groups (P = 0.08). 
Data from n = 14 children with CP (CP_C), n = 10 healthy 
adults (Con_A), and n = 10 adults with CP (CP_A) are shown. 
The plasma CRP levels of one CP_C sample were under the 
detectable range and are therefore missing. Furthermore, the 
IL-6 plasma levels of six samples were under the detectable 
range and are therefore missing.
The symbol “*” indicates a significant difference between the children 
with CP (CP_C) and the other two groups (adults with CP (CP_A) and 
healthy control adults (Con_A)); “#” indicates a significant difference 
between the children with CP (CP_C) and the adults with CP (CP_A). 
The level of significance was P < 0.05.
6 European Journal of Inflammation
Funding
The author(s) disclosed receipt of the following financial 
support for the research, authorship, and/or publication of 
this article: This project was funded by the Danish research 
Council (DFF-1333-00197) and the Elsass Foundation.
ORCID iD
Jessica Pingel  https://orcid.org/0000-0002-9977-094X
References
 1. Mathewson MA and Lieber RL. Pathophysiology 
of muscle contractures in cerebral palsy. Physical 
Medicine and Rehabilitation Clinics of North America 
2015; 26(1): 57–67.
 2. Sewell MD, Eastwood DM and Wimalasundera N. 
Managing common symptoms of cerebral palsy in 
children. BMJ 2014; 349: g5474.
 3. Peterson MD, Ryan Mj, Hurvitz EA et al. Chronic 
conditions in adults with cerebral palsy. JAMA 2015; 
314(21): 2303–2305.
 4. Pedersen BK. IL-6 signalling in exercise and dis-
ease. Biochemical Society Transactions 2007; 35(Pt 
5): 1295–1297.
 5. von Walden F, Gantelius S, Liu C et al. Muscle con-
tractures in patients with cerebral palsy and acquired 
brain injury are associated with extracellular matrix 
expansion, pro-inflammatory gene expression, and reduced 
rRNA synthesis. Muscle Nerve 2018; 58: 277–285.
 6. Nozoe M, Kanai M, Kubo H et al. Changes in quadriceps 
muscle thickness, disease severity, nutritional status, and 
C-reactive protein after acute stroke. Journal of Stroke & 
Cerebrovascular Diseases 2016; 25(10): 2470–2474.
 7. Belizario JE, Fontes-Oliveira CC, Borges JP et al. 
Skeletal muscle wasting and renewal: a pivotal role of 
myokine IL-6. SpringerPlus 2016; 5: 619.
 8. Jahnsen R, Villien L, Egeland T et al. Locomotion 
skills in adults with cerebral palsy. Clinical 
Rehabilitation 2004; 18(3): 309–316.
 9. Dowd JB, Zajacova A and Aiello AE. Predictors of inflam-
mation in U.S. children aged 3-16 years. American 
Journal of Preventive Medicine 2010; 39(4): 314–320.
 10. Kuban KC, O’Shea TM, Allred EN et al. Systemic 
inflammation and cerebral palsy risk in extremely 
preterm infants. Journal of Child Neurology 2014; 
29(12): 1692–1698.
 11. Handschin C and Spiegelman BM. The role of exer-
cise and PGC1alpha in inflammation and chronic dis-
ease. Nature 2008; 454(7203): 463–469.
 12. Toth MJ, Matthews DE, Tracy R et al. Age-related dif-
ferences in skeletal muscle protein synthesis: relation 
to markers of immune activation. American Journal 
of Physiology-Endocrinology and Metabolism 2005; 
288(5): E883–E891.
